Biologics for chronic plaque psoriasis

Researchers have investigated biologics for chronic plaque psoriasis and major adverse cardiovascular events (MACEs)

The researchers selected 22 randomised, controlled, double-blind monotherapy studies of IL-12/23 antibodies and anti-TNF-alpha agents in adults. Analysis of patients on anti-IL12/23 revealed that 10 out of 3,179 experienced a MACE, compared with none of the 1,474 patients on placebo. One of the 3,858 patients on anti-TNF-alpha agents experienced a MACE, compared with one of the 1,812 patients on placebo. The authors conclude there was no significant difference in the rate of MACEs in patients treated with biologics compared with placebo.
Ryan C, Leonardi CL, James G et al. JAMA 2011; 306: 864-71

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more